Literature DB >> 606629

Clinical study of liver blood flow in man measured by 133Xe clearance after portal vein injection.

S B Sherriff, R C Smart, I Taylor.   

Abstract

During the course of a clinical trial to assess the value of adjuvant liver perfusion of 5-fluorouracil after surgery for colorectal cancer, liver blood flow was measured in 14 patients. Access to the portal circulation was achieved by dilatation and cannulation of the obliterated umbilical vein. The clearance from the liver of a bolus of 133Xe was monitored using a gamma-ray camera so that blood flow from different areas of the liver could be calculated. The clearance curve of 133Xe was a double exponential of which the initial fast component accounted for a consistently high proportion of the total clearance. The perfusion studies have shown wide differences in blood flow to the various areas of the liver in the same patient, in addition to a wide variation in perfusion rate between the 14 patients. This technique of quantitative estimations of liver blood flow to different areas of the liver may have importance in planning operative procedures and understanding the haemodynamic mechanisms involved in liver disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606629      PMCID: PMC1411835          DOI: 10.1136/gut.18.12.1027

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  HEPATIC BLOOD-FLOW MEASUREMENT WITH XENON 133. EVIDENCE FOR SEPARATE HEPATIC-ARTERIAL AND PORTAL-VENOUS PATHWAYS.

Authors:  J R REES; V J REDDING; R ASHFIELD
Journal:  Lancet       Date:  1964-09-12       Impact factor: 79.321

2.  Equilibrium distribution of radioxenon in tissue: xenon-hemoglobin association curve.

Authors:  H L CONN
Journal:  J Appl Physiol       Date:  1961-11       Impact factor: 3.531

3.  The theory and applications of the exchange of inert gas at the lungs and tissues.

Authors:  S S KETY
Journal:  Pharmacol Rev       Date:  1951-03       Impact factor: 25.468

4.  Regional hepatic blood flow studied by intrahepatic injection of 133 xenon in normals and in patients with primary carcinoma of the liver, with particular reference to the effect of hepatic artery ligation.

Authors:  U Plengvanit; R Suwanik; O Chearanai; S Intrasupt; S Sutayavanich; C Kalayasiri; V Viranuvatti
Journal:  Aust N Z J Med       Date:  1972-02

5.  Investigation of the portal circulation via the umbilical vein.

Authors:  B Man; L Kraus; S Pikielny
Journal:  Vasc Surg       Date:  1974 May-Jun

6.  Studies of blood flow and ultrastructural changes in rejecting and nonrejecting canine orthotopic liver homografts.

Authors:  C G Groth; K A Porter; J B Otte; P M Daloze; T L Marchioro; L Brettschneider; T E Starzl
Journal:  Surgery       Date:  1968-04       Impact factor: 3.982

7.  The effect of heparin on the initial phase of metastasis formation.

Authors:  P Hilgard; L Beyerle; R Hohage; V Hiemeyer; M Kübler
Journal:  Eur J Cancer       Date:  1972-06       Impact factor: 9.162

8.  Transumbilical portal decompression.

Authors:  V A Piccone; H H LeVeen
Journal:  Surg Gynecol Obstet       Date:  1967-07

9.  Liver blood flow in man during abdominal surgery. 1. Description of a method utilizing intrahepatic injections of radioactive xenon (133Xe). Normal values and effect of temporary occulsion.

Authors:  L E Gelin; D H Lewis; L Nilsson
Journal:  Acta Hepatosplenol       Date:  1968 Jan-Feb

10.  Hepatic blood flow in dogs measured by Xe133 clearance technique.

Authors:  B G Danielson; B Karlmark
Journal:  Acta Soc Med Ups       Date:  1970
View more
  9 in total

1.  Measurement of liver blood flow using oxygen-15 labelled water and dynamic positron emission tomography: limitations of model description.

Authors:  S I Ziegler; U Haberkorn; H Byrne; C Tong; S Kaja; J A Richolt; H Byrne; C Tong; R Schosser; H Krieter; S Kaja; J A Richolt; A A Lammertsma; P Price
Journal:  Eur J Nucl Med       Date:  1996-02

2.  Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver.

Authors:  Chaan S Ng; Adam G Chandler; Wei Wei; Ella F Anderson; Delise H Herron; Razelle Kurzrock; Chusilp Charnsangavej
Journal:  J Comput Assist Tomogr       Date:  2012 Jul-Aug       Impact factor: 1.826

3.  The prevention of arterial collaterals after repeated temporary blockade of the hepatic artery in pigs.

Authors:  B G Persson; B Jeppsson; L Andersson; S E Strand; L Ekelund; S Bengmark
Journal:  World J Surg       Date:  1987-10       Impact factor: 3.352

4.  Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values.

Authors:  Chaan S Ng; Brian P Hobbs; Adam G Chandler; Ella F Anderson; Delise H Herron; Chusilp Charnsangavej; James Yao
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

Review 5.  Portal circulation and portal hypertension.

Authors:  S Sherlock
Journal:  Gut       Date:  1978-01       Impact factor: 23.059

6.  A multiscale modelling approach to assess the impact of metabolic zonation and microperfusion on the hepatic carbohydrate metabolism.

Authors:  Nikolaus Berndt; Marius Stefan Horger; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  PLoS Comput Biol       Date:  2018-02-15       Impact factor: 4.475

7.  The blood supply of colorectal liver metastases.

Authors:  I Taylor; R Bennett; S Sherriff
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

8.  129 Xe chemical shift in human blood and pulmonary blood oxygenation measurement in humans using hyperpolarized 129 Xe NMR.

Authors:  Graham Norquay; General Leung; Neil J Stewart; Jan Wolber; Jim M Wild
Journal:  Magn Reson Med       Date:  2016-04-08       Impact factor: 4.668

9.  Computational Hypothesis: How Intra-Hepatic Functional Heterogeneity May Influence the Cascading Progression of Free Fatty Acid-Induced Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Hermann-Georg Holzhütter; Nikolaus Berndt
Journal:  Cells       Date:  2021-03-05       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.